Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study

CONCLUSIONS: Mepolizumab at a "severe asthma" dose (100mg/4weeks) is effective in treatment of GC-dependent severe asthma in most patients with EGPA.PMID:37923651 | DOI:10.1016/j.rmr.2023.10.003

Source: Revue des Maladies Respiratoires - November 3, 2023 Category: Respiratory Medicine Authors: F Akdime S Habib L Regard B Terrier P Cohen L Mouthon L Guillevin P R Burgel I Honore X Pu échal N Roche Source Type: research